01:37 , May 5, 2017 |  BC Week In Review  |  Company News

Pieris, AZ in respiratory deal for Anticalins

Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) worldwide rights to develop and commercialize five inhaled respiratory disease candidates developed using the biotech's Anticalin platform. The deal includes preclinical asthma candidate PRS-060 and four...
22:08 , May 3, 2017 |  BC Extra  |  Company News

Pieris, AZ in respiratory deal for Anticalins

Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) climbed $1.27 (53%) to $3.67 after it said it partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) to advance up to five respiratory disease candidates developed using the biotech's Anticalin platform, including one...
07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-4 (IL-4; BSF1); IL-4 receptor (CD124; IL-4RA); interleukin-13 (IL-13)

Gastrointestinal disease INDICATION: Pancreatitis In vitro and mouse studies suggest inhibiting IL-4 and IL-13 could help treat chronic pancreatitis. In pancreatic tissues from a mouse model of chronic pancreatitis or from patients with the disease, numbers of...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Company News

Pieris, Pieris Pharmaceuticals deal

Pieris AG, Freising-Weihenstephan, Germany   Pieris Pharmaceuticals Inc. (Pink:PIRS), Freising-Weihenstephan, Germany   Business: Hematology, Inflammation   Pieris AG reverse-merged with Pieris Pharmaceuticals Inc. (formerly shell company Marika Inc.) and began trading on the Pink Sheets. The surviving company,...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Clinical News

Pieris preclinical data

In rats, pulmonary delivery of PRS-060 showed 10-fold higher bioavailability than historical data for pulmonary delivery of monoclonal antibodies. Pieris is developing PRS-060, an anticalin, for asthma. Pieris AG, Freising, Germany   Product: PRS-060   Indication:...